Merck & Co Inc. (MRK) on Wednesday said the U.S. Food and Drug Administration has approved Keytruda and Keytruda Qlx, a subcutaneous formulation of Keytruda, in combination with paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1 positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one or two prior systemic therapies.
The approvals are based on results from the Phase 3 KEYNOTE-B96 trial. The study showed that Keytruda plus paclitaxel, with or without bevacizumab, significantly improved progression-free survival, reducing the risk of disease progression or death by 28% compared with placebo plus paclitaxel, with or without bevacizumab.
In the same patient population, the Keytruda regimen also demonstrated a statistically significant improvement in overall survival, reducing the risk of death by 24% versus the comparator treatment.
The immunotherapy drug Keytruda is approved to treat multiple types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell cancer, and classical Hodgkin lymphoma, among others.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.